Microspot Immunoassay-Based Analysis of Plasma Protein Profiles for Biomarker Discovery Strategies

Methods in Molecular Biology

Volumn 785, Issue , 2011, Pages 237-245

  Sonntag, Johanna ^a   Mannsperger, Heiko ^a   Jöcker, Anika ^a   Korf, Ulrike ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antibody microarray; Biomarker; Microspot immunoassay; Multiplex ELISA; Personalized medicine; Plasma; QuantProReloaded

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; PLASMA PROTEIN;

ARTICLE; BLOOD; HUMAN; IMMUNOASSAY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; PERSONALIZED MEDICINE; PROTEIN MICROARRAY;

ANTIBODIES; BIOLOGICAL MARKERS; BLOOD PROTEINS; HUMANS; IMMUNOASSAY; INDIVIDUALIZED MEDICINE; PROTEIN ARRAY ANALYSIS;

EID: 80054771972     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-286-1_16     Document Type: Chapter

References (16)

1. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Clin Pharmacol Ther 69, 89–95.
2. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus, Diabetes Care 33 Suppl 1, S62-69.
3. Donegan, W. L. (1992) Prognostic factors. Stage and receptor status in breast cancer, Cancer 70, 1755–1764.
4. Donnelly, J. G. (2004) Pharmacogenetics in cancer chemotherapy: balancing toxicity and response, Ther Drug Monit 26, 231–235.
5. Dunn, L., and Demichele, A. (2009) Genomic predictors of outcome and treatment response in breast cancer, Mol Diagn Ther 13, 73–90.
6. Duffy, M. J., and Crown, J. (2008) A personalized approach to cancer treatment: how biomarkers can help, Clin Chem 54, 1770–1779.
7. Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., and Senn, H. J. (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009, Ann Oncol 20, 1319–1329.
8. Lilja, H., Ulmert, D., and Vickers, A. J. (2008) Prostate-specific antigen and prostate cancer: prediction, detection and monitoring, Nat Rev Cancer 8, 268–278.
9. Molina, R., Barak, V., van Dalen, A., Duffy, M. J., Einarsson, R., Gion, M., Goike, H., Lamerz, R., Nap, M., Soletormos, G., and Stieber, P. (2005) Tumor markers in breast cancer-European Group on Tumor Markers recommendations, Tumour Biol 26, 281–293.
10. Hanash, S. M., Pitteri, S. J., and Faca, V. M. (2008) Mining the plasma proteome for cancer biomarkers, Nature 452, 571–579.
11. Rai, A. J. (2007) Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays, Expert Rev Mol Diagn 7, 545–553.
12. Jöcker, A., Sonntag, J., Henjes, F., Gotschel, F., Tresch, A., Beissbarth, T., Wiemann, S., and Korf, U. (2010) QuantProReloaded: quantitative analysis of microspot immunoassays, Bioinformatics 26, 2480–2481.
13. Sweep, F. C. G. J., Thomas, C. M. G., and Schmitt, M. (2006) Analytical aspects of biomarker immunoassays in cancer research, in Biomarkers in breast cancer: Molecular diagnostics for predicting and monitoring therapeutic effect (Gasparini, G., and Hayes, D. F., Eds.), pp 17–30, Humana Press.
14. Gonzalez, R. M., Seurynck-Servoss, S. L., Crowley, S. A., Brown, M., Omenn, G. S., Hayes, D. F., and Zangar, R. C. (2008) Development and validation of sandwich ELISA microarrays with minimal assay interference, J Proteome Res 7, 2406–2414.
15. Jelkmann, W. (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor, Clin Chem 47, 617–623.
16. Rai, A. J., Gelfand, C. A., Haywood, B. C., Warunek, D. J., Yi, J., Schuchard, M. D., Mehigh, R. J., Cockrill, S. L., Scott, G. B., Tammen, H., Schulz-Knappe, P., Speicher, D. W., Vitzthum, F., Haab, B. B., Siest, G., and Chan, D. W. (2005) HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples, Proteomics 5, 3262–3277.